Soluble and membrane-bound adenylate kinase and nucleotidases augment ATP-mediated inflammation in diabetic retinopathy eyes with vitreous hemorrhage.


Journal

Journal of molecular medicine (Berlin, Germany)
ISSN: 1432-1440
Titre abrégé: J Mol Med (Berl)
Pays: Germany
ID NLM: 9504370

Informations de publication

Date de publication:
03 2019
Historique:
received: 30 07 2018
accepted: 17 12 2018
revised: 23 11 2018
pubmed: 9 1 2019
medline: 6 6 2020
entrez: 9 1 2019
Statut: ppublish

Résumé

ATP and adenosine are important signaling molecules involved in vascular remodeling, retinal function, and neurovascular coupling in the eye. Current knowledge on enzymatic pathways governing the duration and magnitude of ocular purinergic signaling is incompletely understood. By employing sensitive analytical assays, this study dissected ocular purine homeostasis as a complex and coordinated network. Along with previously characterized ecto-5'-nucleotidase/CD73 and adenylate kinase activities, other enzymes have been identified in vitreous fluids, including nucleoside triphosphate diphosphohydrolase (NTPDase), adenosine deaminase, and alkaline phosphatase. Strikingly, activities of soluble adenylate kinase, adenosine deaminase, ecto-5'-nucleotidase/CD73, and alkaline phosphatase, as well as intravitreal concentrations of ATP and ADP, were concurrently upregulated in patients suffering from diabetic retinopathy (DR) with non-clearing vitreous hemorrhage (VH), when compared to DR eyes without VH and control eyes operated due to macular hole or pucker. Additional histochemical analysis revealed selective distribution of key ecto-nucleotidases (NTPDase1/CD39, NTPDase2, ecto-5'-nucleotidase/CD73, and alkaline phosphatase) in the human sensory neuroretina and optic nerve head, and also in pathological neofibrovascular tissues surgically excised from patients with advanced proliferative DR. Collectively, these data provide evidence for specific hemorrhage-related shifts in purine homeostasis in DR eyes from the generation of anti-inflammatory adenosine towards a pro-inflammatory and pro-angiogenic ATP-regenerating phenotype. In the future, identifying the exact mechanisms by which a broad spectrum of soluble and membrane-bound enzymes coordinately regulates ocular purine levels and the further translation of purine-converting enzymes as potential therapeutic targets in the treatment of proliferative DR and other vitreoretinal diseases will be an area of intense interest. KEY MESSAGES: NTPDase, alkaline phosphatase, and adenosine deaminase circulate in human vitreous. Purinergic enzymes are up-regulated in diabetic eyes with vitreous hemorrhage. Soluble adenylate kinase maintains high ATP levels in diabetic retinopathy eyes. Ecto-nucleotidases are co-expressed in the human retina and optic nerve head. Alkaline phosphatase is expressed on neovascular tissues excised from diabetic eyes.

Identifiants

pubmed: 30617853
doi: 10.1007/s00109-018-01734-0
pii: 10.1007/s00109-018-01734-0
pmc: PMC6394560
doi:

Substances chimiques

Adenosine Diphosphate 61D2G4IYVH
Adenosine Triphosphate 8L70Q75FXE
Adenylate Kinase EC 2.7.4.3
Nucleotidases EC 3.1.3.-
Alkaline Phosphatase EC 3.1.3.1
Adenosine K72T3FS567

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

341-354

Références

Am J Pathol. 2012 Jan;180(1):419-28
pubmed: 22074736
J Ocul Pharmacol Ther. 2016 Oct;32(8):534-547
pubmed: 27574786
Purinergic Signal. 2012 Sep;8(3):437-502
pubmed: 22555564
Vision Res. 2005 Dec;45(28):3504-11
pubmed: 16213000
J Med Chem. 2015 Aug 13;58(15):6248-63
pubmed: 26147331
Philos Trans R Soc Lond B Biol Sci. 2015 Jul 5;370(1672):
pubmed: 26009774
Photochem Photobiol Sci. 2003 Dec;2(12):1299-302
pubmed: 14717224
J Pharmacol Exp Ther. 2013 Jun;345(3):331-41
pubmed: 23504005
Prog Retin Eye Res. 2003 Jan;22(1):95-111
pubmed: 12597925
Exp Eye Res. 2014 Oct;127:270-9
pubmed: 25151301
Trends Neurosci. 2009 Mar;32(3):128-41
pubmed: 19232752
JCI Insight. 2017 Jul 20;2(14):
pubmed: 28724805
Acta Ophthalmol. 2015 Feb;93(1):67-73
pubmed: 25079888
Purinergic Signal. 2006 Jun;2(2):409-30
pubmed: 18404480
Int J Mol Sci. 2009 Apr 17;10(4):1729-72
pubmed: 19468337
Biochem Pharmacol. 2015 Jan 15;93(2):171-81
pubmed: 25449596
Invest Ophthalmol Vis Sci. 2015 May;56(5):3075-83
pubmed: 26024091
Biochim Biophys Acta. 2013 Apr;1830(4):2882-90
pubmed: 23328492
Pharmacol Rev. 1998 Sep;50(3):413-92
pubmed: 9755289
Crit Rev Biochem Mol Biol. 2014 Nov-Dec;49(6):473-97
pubmed: 25418535
Invest Ophthalmol Vis Sci. 2000 Jan;41(1):218-29
pubmed: 10634624
Am J Pathol. 2017 Aug;187(8):1670-1685
pubmed: 28628761
Vision Res. 1999 Jul;39(15):2519-35
pubmed: 10396621
Front Neuroanat. 2016 Apr 29;10:46
pubmed: 27199678
Acta Ophthalmol. 2013 Sep;91(6):531-9
pubmed: 23106921
Ophthalmologica. 2013;230(4):165-78
pubmed: 23989078
Prog Retin Eye Res. 2007 Nov;26(6):674-87
pubmed: 17931952
J Biol Chem. 2006 Oct 6;281(40):29441-7
pubmed: 16885159
PLoS One. 2013;8(1):e53338
pubmed: 23308196
Biochim Biophys Acta. 2012 Oct;1823(10):1967-75
pubmed: 22967714
Cell Tissue Res. 2008 Nov;334(2):199-217
pubmed: 18843508
Purinergic Signal. 2007 Sep;3(4):423-33
pubmed: 18404455
Exp Eye Res. 2009 Apr;88(4):738-46
pubmed: 19084518
Nat Commun. 2017 Sep 19;8(1):584
pubmed: 28928465
J Mol Med (Berl). 2017 Feb;95(2):193-204
pubmed: 27638339
Mol Cell Biochem. 2004 Jan-Feb;256-257(1-2):59-72
pubmed: 14977170
FASEB J. 2003 Jul;17(10):1328-30
pubmed: 12759341
Neuropharmacology. 2016 May;104:194-211
pubmed: 25998275
Int J Mol Sci. 2018 Mar 22;19(4):
pubmed: 29565290
Biochim Biophys Acta. 2008 May;1783(5):673-94
pubmed: 18302942
J Pathol. 2018 Jun;245(2):172-185
pubmed: 29536540
FASEB J. 2012 Sep;26(9):3875-83
pubmed: 22637533
Prog Retin Eye Res. 2015 Sep;48:160-80
pubmed: 25936649
J Neurosci. 2013 Feb 13;33(7):3135-50
pubmed: 23407968
World J Diabetes. 2015 Apr 15;6(3):489-99
pubmed: 25897358
Stem Cells. 2015 Jan;33(1):253-64
pubmed: 25205248
Nat Rev Drug Discov. 2012 Jun 15;11(7):541-59
pubmed: 22699774
Adv Enzymol Relat Areas Mol Biol. 1999;73:103-34, x
pubmed: 10218107

Auteurs

Julian Zeiner (J)

MediCity Research Laboratory, University of Turku, Tykistökatu 6A, 20520, Turku, Finland.
Pharma Center Bonn, Pharmaceutical Institute, University of Bonn, Bonn, Germany.

Sirpa Loukovaara (S)

Unit of Vitreoretinal Surgery, Department of Ophthalmology, Helsinki University Central Hospital and University of Helsinki, Helsinki, Finland.

Karolina Losenkova (K)

MediCity Research Laboratory, University of Turku, Tykistökatu 6A, 20520, Turku, Finland.

Mariachiara Zuccarini (M)

MediCity Research Laboratory, University of Turku, Tykistökatu 6A, 20520, Turku, Finland.

Ani M Korhonen (AM)

Research Programs Unit, Genome-Scale Biology, University of Helsinki, Helsinki, Finland.

Kaisa Lehti (K)

Research Programs Unit, Genome-Scale Biology, University of Helsinki, Helsinki, Finland.
Department of Microbiology, Tumor and Cell Biology, Karolinska Institutet, Stockholm, Sweden.

Anu Kauppinen (A)

School of Pharmacy, Faculty of Health Sciences, University of Eastern Finland, Kuopio, Finland.

Kai Kaarniranta (K)

Department of Ophthalmology, Kuopio University Hospital, Kuopio, Finland.
Department of Ophthalmology, Institute of Clinical Medicine, University of Eastern Finland, Kuopio, Finland.
Department of Molecular Genetics, Faculty of Biology and Environmental Protection, University of Lodz, Lodz, Poland.

Christa E Müller (CE)

Pharma Center Bonn, Pharmaceutical Institute, University of Bonn, Bonn, Germany.

Sirpa Jalkanen (S)

MediCity Research Laboratory, University of Turku, Tykistökatu 6A, 20520, Turku, Finland.

Gennady G Yegutkin (GG)

MediCity Research Laboratory, University of Turku, Tykistökatu 6A, 20520, Turku, Finland. genyeg@utu.fi.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH